Leslie J. Williams is a seasoned biopharmaceutical leader with extensive experience in founding and leading biotech companies. As Co-Founder, President, and CEO of HC Bioscience, she is pioneering the development of new genetic medicines utilizing engineered tRNA to target nonsense mutations responsible for 10-15% of genetic diseases. Previously, Leslie was Founder and CEO of ImmusanT, advancing immunotherapies for autoimmune diseases. She has also served as CEO of Ventaira Pharmaceuticals, where she helped develop pulmonary drug delivery technology, and was a founding member of the team at INO Therapeutics, which developed a treatment for pulmonary hypertension. Leslie currently serves on the Board of Directors for Ocular Therapeutix (Nasdaq: OCUL), Windtree Therapeutics (Nasdaq: WINT), Biotechnology Innovation Organization (BIO), and CSCRI (Coral Sea Clinical Research Institute) as well as the Board of Advisors of Life Science Cares and the Editorial Advisory Board of Life Science Leader. She is also a founding Ambassador of BioBoost and a mentor at the GLG Institute. Williams holds an MBA from Washington University, John Olin School of Business and a bachelor’s degree nursing from the University of Iowa. Before entering the biopharmaceutical industry, Leslie was a critical care nurse at Duke University, Medical College of Virginia, and the University of Iowa. Leslie has been recognized for her contributions with numerous awards, including Distinguished Alumni and Honorary Alumni honors from the University of Iowa.